Asha Karippot
A5021960209- Fibroblast Growth Factor Research
- Medical Imaging and Pathology Studies
- Sarcoma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Venous Thromboembolism Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Cardiac tumors and thrombi
- Medical Imaging Techniques and Applications
- Intestinal and Peritoneal Adhesions
- Acute Myeloid Leukemia Research
- Magnesium in Health and Disease
- Central Venous Catheters and Hemodialysis
- Cancer and Skin Lesions
- Chemotherapy-induced cardiotoxicity and mitigation
- Parathyroid Disorders and Treatments
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
- Rabies epidemiology and control
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Ovarian cancer diagnosis and treatment
Texas Oncology
2023-2024
Cancer Treatment Centers of America
2018-2024
St. Joseph’s University Medical Center
2009-2012
Seton Hall University
2009-2012
St. Joseph Regional Medical Center
2009-2012
Saint Michael's Medical Center
2009
To develop an evidence-based clinical practice guideline to assist in decision making for patients with advanced hepatocellular carcinoma (HCC).
To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor FGFR1-3, in patients with solid tumors harboring a functional FGFR1-3 fusion.
End stage renal disease (ESRD) population account for 1.9 per patient year of hospital admissions annually. ESRD are at increased risk bleeding secondary to use anticoagulation during hemodialysis and uremia induced platelet dysfunction. Gastrointestinal accounts 3–7% all deaths in population. Lower gastrointestinal refers blood loss from a site the tract distal ligament Treitz. It is usually suspected when complains hematochezia. different patients presenting with hematemesis that suggests...
Skin metastases from advanced colorectal cancer are relatively rare and occur most often when the is advanced, following spread to other organs. Cutaneous in about 3% of cancers. We present an extremely case a 68-year-old woman with ascending colon adenocarcinoma that presented multiple rapidly progressing painless cutaneous metastatic lesions no distant metastases. Of all tumors, breast commonly spreads as metastasis followed by lung, colorectal, renal, ovarian, bladder can variety clinical...
The venous thromboembolic complication, pulmonary embolism (PE), is an important cause of death in cancer patients.[1–3] Depending on the clinical presentation, case fatality rate for acute ranges from about 60% to less than 1%.[4] in-hospital mortality general medical and surgical patients with PE up 6% a 30-day 9.3% 3-month 15.3%.[5]
<p>Supplementary Figure S2. Progression-free survival.</p>
<p>Supplementary methods</p>
<p>Supplementary Figure S1. Study CONSORT diagram.</p>
<div>AbstractPurpose:<p>This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor FGFR1–3, in patients with solid tumors harboring a functional <i>FGFR1–3</i> fusion.</p>Patients Methods:<p>Eligible adults had previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial 2),...